[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
5. Fernández Y, Bernabeu-Wittel M, García-Morillo JS: Kaposiform hemangioendothelioma. Eur J Intern Med; 2009 Mar;20(2):106-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposiform hemangioendothelioma.
  • Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular neoplasm that mainly occurs during childhood.
  • It generally originates on the skin, usually affecting deeper tissue by infiltrative growth.
  • On the other hand, bulk visceral masses lead to a 40-50% mortality rate, mainly due to progressive failure of the infiltrated organ(s), in spite of interferon, glucocorticoids, and combined chemotherapy.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / therapy

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Kaposiform Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327597.001).
  • [ISSN] 1879-0828
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 87
  •  go-up   go-down


6. Suda T, Hashizume H, Aoshima Y, Yokomura K, Sato J, Inui N, Nakamura Y, Fujisawa T, Enomoto N, Chida K: Management of interleukin-2-induced severe bronchoconstriction. Eur Respir J; 2007 Mar;29(3):612-3
Hazardous Substances Data Bank. ALBUTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adrenergic beta-Agonists / administration & dosage. Albuterol / analogs & derivatives. Androstadienes / administration & dosage. Anti-Inflammatory Agents / administration & dosage. Antineoplastic Agents / adverse effects. Bronchial Diseases / chemically induced. Bronchial Diseases / drug therapy. Bronchodilator Agents / administration & dosage. Hemangioendothelioma / drug therapy. Interleukin-2 / adverse effects. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Inhalation. Aged. Aged, 80 and over. Constriction, Pathologic / chemically induced. Constriction, Pathologic / drug therapy. Delayed-Action Preparations. Drug Administration Schedule. Female. Fluticasone. Forced Expiratory Volume / drug effects. Humans. Infusions, Intravenous. Injections, Intralesional. Male. Middle Aged. Premedication. Salmeterol Xinafoate

  • MedlinePlus Health Information. consumer health - Bronchial Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329497.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Androstadienes; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Bronchodilator Agents; 0 / Delayed-Action Preparations; 0 / Interleukin-2; 6EW8Q962A5 / Salmeterol Xinafoate; CUT2W21N7U / Fluticasone; QF8SVZ843E / Albuterol
  •  go-up   go-down


7. Park EA, Seo JW, Lee SW, Choi HY, Lee SJ: Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy. J Korean Med Sci; 2001 Feb;16(1):127-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy.
  • Infantile hemangioendothelioma is a severe disease with a high mortality.
  • It is characterized by multiple hemangioma affecting the skin and visceral organs.
  • We report that high doses of methylprednisolone pulse therapy improved symptoms and signs of infantile hemangioendothelioma in a male neonate, and completely resolved the hepatic and cutaneous hemangioendothelioma on follow up.
  • [MeSH-major] Hemangioendothelioma / drug therapy. Liver Neoplasms / drug therapy. Methylprednisolone / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11289392.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC3054580
  •  go-up   go-down


8. Sevinir B, Ozkan TB: Infantile hepatic hemangioendothelioma: clinical presentation and treatment. Turk J Gastroenterol; 2007 Sep;18(3):182-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hepatic hemangioendothelioma: clinical presentation and treatment.
  • METHODS: This retrospective analysis included eight patients with infantile hepatic hemangioendothelioma.
  • Most of the multifocal hepatic tumors were associated with skin hemangiomas.
  • Treatment options were assessed individually.
  • Systemic prednisolone therapy (2 mg/kg/d) was commenced in six patients.
  • One boy with Kasabach-Merritt syndrome did not respond to this therapy.
  • Interferon-alpha (1 million units (MU)/m2/day) was started, and the daily dose of the drug was increased up to 10 MU/m2, administered 3 times per week, until clinical improvement was achieved.
  • CONCLUSIONS: The treatment approaches depend on the center's experience.
  • A multidisciplinary approach is required for the best treatment option.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Abdomen. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Dilatation, Pathologic / etiology. Female. Glucocorticoids / therapeutic use. Hemangioma / diagnosis. Hepatomegaly / etiology. Humans. Immunologic Factors / therapeutic use. Infant. Infant, Newborn. Interferon-alpha / therapeutic use. Male. Neoplasms, Multiple Primary. Prednisolone / therapeutic use. Respiratory Distress Syndrome, Newborn / etiology. Retrospective Studies. Skin Neoplasms / diagnosis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891692.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunologic Factors; 0 / Interferon-alpha; 9PHQ9Y1OLM / Prednisolone; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


9. Tamai N, Hashii Y, Osuga K, Chihara T, Morii E, Aozasa K, Yoshikawa H: Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon. Skeletal Radiol; 2010 Oct;39(10):1043-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon.
  • Kaposiform hemangioendothelioma (KHE) is a rare tumor that occurs nearly exclusively during infancy and childhood.
  • It has features common to both capillary hemangioma and Kaposi sarcoma and for that reason many terms have been used for these tumors including "Kaposi-like infantile hemangioendothelioma" and "hemangioma with Kaposi sarcoma-like features."
  • We present the MRI features of a case of KHE with neither typical skin lesions nor the Kasabach-Merritt phenomenon.
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Deltoid Muscle / pathology. Deltoid Muscle / ultrastructure. Diagnosis, Differential. Disseminated Intravascular Coagulation. Hemangioendothelioma / diagnosis. Hemangioendothelioma / drug therapy. Hemangioendothelioma / ultrastructure. Hemangioma, Capillary. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / drug therapy. Hemangioma, Cavernous / ultrastructure. Humans. Infant. Kasabach-Merritt Syndrome. Magnetic Resonance Imaging / methods. Male. Prednisolone / therapeutic use. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / ultrastructure. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Skin Neoplasms / ultrastructure. Thrombocytopenia / diagnosis. Thrombocytopenia / drug therapy. Treatment Outcome. Vascular Neoplasms / diagnosis. Vascular Neoplasms / drug therapy. Vascular Neoplasms / ultrastructure

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Kaposiform Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):616-22 [15793511.001]
  • [Cites] Head Neck. 2006 Aug;28(8):761-4 [16721737.001]
  • [Cites] Skeletal Radiol. 2009 Jun;38(6):535-47 [19020874.001]
  • [Cites] J Pediatr Surg. 2006 Aug;41(8):1486-8 [16863862.001]
  • [Cites] Adv Anat Pathol. 2003 Mar;10(2):69-87 [12605089.001]
  • [Cites] Adv Dermatol. 1997;13:375-423 [9551150.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):321-8 [8494101.001]
  • [Cites] Br J Plast Surg. 2002 Mar;55(2):163-5 [11987956.001]
  • [Cites] Dermatol Clin. 1998 Jul;16(3):455-88 [9704205.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):931-3 [16611794.001]
  • [Cites] Skeletal Radiol. 1997 Nov;26(11):654-8 [9428073.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):559-68 [15105642.001]
  • [Cites] J Pediatr Surg. 2008 Jan;43(1):e37-41 [18206444.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1087-92 [11706068.001]
  • [Cites] Br J Radiol. 2009 Mar;82(975):e51-4 [19211904.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):225-35 [10642677.001]
  • [Cites] Skeletal Radiol. 2006 Mar;35(3):127-37 [16447042.001]
  • [Cites] Skeletal Radiol. 2004 Jul;33(7):409-12 [15205928.001]
  • (PMID = 20309545.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone; Kaposiform Hemangioendothelioma
  •  go-up   go-down


10. Chen CC, Kong MS, Yang CP, Hung IJ: Hepatic hemangioendothelioma in children: analysis of thirteen cases. Acta Paediatr Taiwan; 2003 Jan-Feb;44(1):8-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic hemangioendothelioma in children: analysis of thirteen cases.
  • Hepatic hemangioendothelioma (HE) is a tumor that presents in infancy and toddler.
  • The common clinical manifestations included abdominal distention (53%), congestive heart failure (38.5%), abdominal mass (30.8%), jaundice (30.8%), and skin hemangioma (23.1%).
  • Computed tomography (n = 11) revealed central hypointensity with peripheral enhancement after contrast of the liver masses.
  • Other management included interferon, chemotherapy, embolization and/or surgery.
  • For its management, steroid is a first-line medication.
  • Other methods of treatment were interferon, hepatic artery embolization, chemotherapy and surgery.
  • Long term follow up is needed for the evaluation of treatment response.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800377.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


11. Walsh R, Harrington J, Beneck D, Ozkaynak MF: Congenital infantile hepatic hemangioendothelioma type II treated with orthotopic liver transplantation. J Pediatr Hematol Oncol; 2004 Feb;26(2):121-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital infantile hepatic hemangioendothelioma type II treated with orthotopic liver transplantation.
  • The authors describe a 10-week-old girl with infantile hepatic hemangioendothelioma who initially presented with difficulty feeding, hepatomegaly, and multiple hemangiomas of the skin.
  • Six weeks of steroid therapy and 2 weeks of chemotherapy failed to produce clinical improvement.
  • A definitive diagnosis of hemangioendothelioma type II was made.
  • Imaging studies cannot differentiate between hemangioendothelioma and angiosarcoma.
  • Treatment modalities for this condition remain unclear.
  • [MeSH-major] Hemangioendothelioma / congenital. Hemangioendothelioma / surgery. Liver Neoplasms / congenital. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Female. Humans. Infant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767204.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1012HP000222
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS: Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer; 2010 Dec 15;55(7):1396-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood kaposiform hemangioendothelioma with sirolimus.
  • Limited experience suggests that it may have application to the treatment of vascular lesions.
  • We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1 mg/kg/day).
  • This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Hemangioendothelioma / drug therapy. Sirolimus / therapeutic use. Skin Neoplasms / drug therapy


13. Drucker AM, Pope E, Mahant S, Weinstein M: Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma. J Cutan Med Surg; 2009 May-Jun;13(3):155-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine and corticosteroids as first-line treatment of Kasabach-Merritt syndrome in kaposiform hemangioendothelioma.
  • BACKGROUND: Historically, patients with the consumptive coagulopathy Kasabach-Merritt syndrome (KMS) have been treated with systemic corticosteroids as first-line therapy, but many patients do not respond.
  • Recently, there have been increasing reports of the use of the chemotherapeutic drug vincristine in these patients.
  • OBJECTIVE: To report a case of a newborn with a kaposiform hemangioendothelioma (KHE) of the right leg associated with KMS treated successfully with vincristine and oral corticosteroids.
  • RESULTS: Treatment with vincristine and corticosteroids lead to sustained shrinking of the tumor and correction of the thrombocytopenia and coagulopathy through 1 year of age.
  • We believe this is the first report in the North American literature of corticosteroids and vincristine being used concomitantly as first-line therapy for KHE with KMS.
  • CONCLUSION: Vincristine and corticosteroids should be considered first-line treatment for KMS.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Blood Coagulation Disorders / drug therapy. Glucocorticoids / therapeutic use. Hemangioendothelioma / drug therapy. Skin / pathology. Vincristine / therapeutic use. Xeroderma Pigmentosum / drug therapy
  • [MeSH-minor] Administration, Oral. Biopsy. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infant, Newborn. Syndrome


1
Advertisement
4. Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindajaran B, Caceres-Rios H, Cotsonis G, Recavarren S, Swerlick RA, Cohen C: Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol; 2001 Feb;44(2):193-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy.
  • Activation of mitogen-activated protein kinase (MAPK) is an important signal transduction mechanism that may predict response of a tumor to chemotherapy.
  • METHODS: Skin sections from benign and malignant endothelial tumors, including hemangioma of infancy, angiosarcoma, and infectious endothelial lesions (Kaposi's sarcoma, verruga peruana) were stained with an antibody specific for phosphorylated MAPK.
  • CONCLUSION: We demonstrate that the use of antibodies specific for signal transduction pathways is feasible in paraffin-fixed tissue.
  • Immunohistochemistry for phosphorylated MAPK may help the pathologist distinguish benign from malignant endothelial processes and thus guide therapy.
  • [MeSH-major] Mitogen-Activated Protein Kinases / analysis. Neoplasms, Vascular Tissue / enzymology. Skin Neoplasms / enzymology
  • [MeSH-minor] Granuloma, Pyogenic / drug therapy. Granuloma, Pyogenic / enzymology. Granuloma, Pyogenic / pathology. Hemangioendothelioma / drug therapy. Hemangioendothelioma / enzymology. Hemangioendothelioma / pathology. Hemangioma / drug therapy. Hemangioma / enzymology. Hemangioma / pathology. Hemangiosarcoma / drug therapy. Hemangiosarcoma / enzymology. Hemangiosarcoma / pathology. Humans. Immunohistochemistry. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / enzymology. Sarcoma, Kaposi / pathology. Skin Diseases / drug therapy. Skin Diseases / enzymology. Skin Diseases / pathology. Warts / drug therapy. Warts / enzymology. Warts / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11174372.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO8 AR02030; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R03AR44947
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


15. Metry DW, Hebert AA: Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol; 2000 Jul;136(7):905-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To discuss 2 newly recognized entities that may be a source of diagnostic confusion with the common hemangioma, the kaposiform hemangioendothelioma and tufted angioma.
  • To discuss the risks and benefits of current treatment options, including the use of systemic corticosteroids and interferon in necessary situations.
  • CONCLUSIONS: The common hemangioma, kaposiform hemangioendothelioma, and tufted angioma, though benign histologically, may cause serious consequences for children.
  • Dermatologists should also be aware of available treatment options, including the use of systemic chemotherapy in life-threatening situations.
  • [MeSH-major] Hemangioma. Skin Neoplasms
  • [MeSH-minor] Abnormalities, Multiple. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioendothelioma / therapy. Humans. Infant. Infant, Newborn. Syndrome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890993.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Koch M, Nielsen GP, Yoon SS: Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol; 2008 Mar 15;97(4):321-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews the management of these three types of sarcomas.
  • The mainstay of treatment is surgical resection, sometimes combined with radiation therapy.
  • Adjuvant chemotherapy is unproven but can be considered.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Hemangiosarcoma / diagnosis. Hemangiosarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Neoplasms, Radiation-Induced. Prognosis. Radiotherapy / adverse effects. Skin Neoplasms / diagnosis. Skin Neoplasms / etiology. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18286475.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


17. Rodriguez V, Lee A, Witman PM, Anderson PA: Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol; 2009 Jul;31(7):522-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kasabach-Merritt phenomenon (KMP) is a rare thrombocytopenic consumption coagulopathy associated with an enlarging tufted angioma or kaposiform hemangioendothelioma.
  • We report a case series of patients with KMP and discuss the treatment options and outcomes.
  • [MeSH-major] Disseminated Intravascular Coagulation / complications. Disseminated Intravascular Coagulation / physiopathology. Hemangioendothelioma / complications. Hemangioma / complications. Skin Neoplasms / complications
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Infant. Male. Radiotherapy. Thrombocytopenia / complications. Thrombocytopenia / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564750.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 10
  •  go-up   go-down


18. McMenamin ME, Fletcher CD: Reactive angioendotheliomatosis: a study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol; 2002 Jun;26(6):685-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reactive angioendotheliomatosis (RAE) is a rare condition characterized by cutaneous vascular proliferation that usually occurs in patients with diverse types of coexistent systemic disease.
  • Eleven patients had coexistent systemic disease: renal disease (six patients, including three post renal transplantation); valvular cardiac disease (two patients); one patient each had alcoholic cirrhosis, glioblastoma multiforme (on chemotherapy), and rheumatoid arthritis/polymyalgia rheumatica.
  • Six patients were iatrogenically immunosuppressed at the onset of the skin lesions.
  • The pathogenesis of this rare disorder is unknown, but it is likely that immunologic factors play a role.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Reactive angioendotheliomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023572.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


19. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Aydingöz IE, Demirkesen C, Serdar ZA, Mansur AT, Yaşar S, Aslan C: Composite haemangioendothelioma with lymph-node metastasis: an unusual presentation at an uncommon site. Clin Exp Dermatol; 2009 Dec;34(8):e802-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite haemangioendothelioma with lymph-node metastasis: an unusual presentation at an uncommon site.
  • Three months later, upon recurrence of the lesions, a diagnosis of composite haemangioendothelioma (CHE) was made.
  • Despite the surgery, a further local recurrence occurred, subsequently treated by wide excision en bloc, with adjuvant radiotherapy and chemotherapy.
  • Although CHE is defined as a vascular tumour with low-grade malignancy, the local recurrences and lymph-node metastases resulted in treatment difficulties in this case.
  • Unlike earlier cases, the tumour in our patient presented as localized numerous small papulonodules, and lymph-node metastasis was detected within a relatively short time.
  • [MeSH-major] Hemangioendothelioma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Thigh / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055844.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC: Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics; 2006 Sep;118(3):e907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a case of a premature female neonate who presented with cardiac failure at birth and had typical-appearing infantile hemangiomas on the skin in association with vascular lesions in the liver.
  • After failure to respond to systemic steroids and chemotherapy, she underwent liver transplantation.
  • Histopathologic evaluation of the liver revealed a diagnosis of type 2 infantile hepatic hemangioendothelioma (regarded as synonymous with angiosarcoma) rather than benign infantile hemangioma of the liver.
  • Subsequent skin biopsies confirmed that her multiple cutaneous lesions were infantile hemangiomas and not metastatic angiosarcoma.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics. 2007 Jun;119(6):1271
  • (PMID = 16880251.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


22. Han K, Haley JC, Carlson K, Pinter-Brown L, Soriano T: Regression of cutaneous intravascular lymphoma with rituximab. Cutis; 2003 Aug;72(2):137-40
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hemangioendothelioma / drug therapy. Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12953938.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Durieu C, Bayle-Lebey P, Gadroy A, Loche F, Bazex J: [Intravascular papillary endothelial hyperplasia: multiple lesions appearing in the course of treatment with interferon beta]. Ann Dermatol Venereol; 2001 Dec;128(12):1336-8
Hazardous Substances Data Bank. Interferon Beta-1a .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravascular papillary endothelial hyperplasia: multiple lesions appearing in the course of treatment with interferon beta].
  • [Transliterated title] Hyperplasie endothéliale papillaire intravasculaire: multiples lésions apparues au cours d'un traitement par interféron bêta.
  • We report a case of multiple vascular lesions of the hand following 3 months treatment with beta-interferon injections for multiple sclerosis.
  • Treatment is surgical and recurrence after treatment is rare.
  • [MeSH-major] Endothelium, Vascular / drug effects. Hemangioendothelioma / chemically induced. Interferon-beta / adverse effects. Multiple Sclerosis, Chronic Progressive / drug therapy. Skin Neoplasms / chemically induced
  • [MeSH-minor] Cell Division / drug effects. Hand / blood supply. Humans. Hyperplasia. Interferon beta-1a. Interferon beta-1b. Male. Middle Aged. Thrombosis / chemically induced. Thrombosis / pathology

  • Genetic Alliance. consumer health - Intravascular papillary endothelial hyperplasia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Interferon Beta-1b .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908138.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 145155-23-3 / Interferon beta-1b; 77238-31-4 / Interferon-beta; XRO4566Q4R / Interferon beta-1a
  •  go-up   go-down


24. Verweij J, Baker LH: Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer; 2010 Mar;46(5):863-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
  • Soft tissue sarcomas, although sharing a mesenchymal origin, are a heterogeneous group of diseases.
  • Genetic profiling studies have indicated that some soft tissue sarcoma subtypes, despite a distinct histo-pathological difference, may be closely related.
  • Molecular biology research in addition has identified several subtype-specific oncogenes and their protein products that could serve as treatment targets.
  • Since many of the new molecularly targeted agents do not induce tumour regression, but mainly result in growth inhibition, it is therefore necessary also to change the study end-point in screening studies in the search for active treatments.
  • In view of all these it is proposed to consider using alternative end-points such as progression-free rates at pre-set times, or progression arrest at first evaluation.
  • Soft tissue sarcoma treatment and research will require a change of approach and necessitate global cooperation.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Cytotoxins / therapeutic use. Sarcoma
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Dermatofibrosarcoma / drug therapy. Dermatofibrosarcoma / genetics. Disease Progression. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / genetics. Hemangioendothelioma / drug therapy. Hemangioendothelioma / genetics. Hemangiosarcoma / drug therapy. Hemangiosarcoma / genetics. Humans. Imatinib Mesylate. Leiomyosarcoma / drug therapy. Leiomyosarcoma / genetics. Liposarcoma, Myxoid / drug therapy. Liposarcoma, Myxoid / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Research Design. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / genetics. Skin Neoplasms / drug therapy. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138507.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cytotoxins; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 62
  •  go-up   go-down


25. Adams DM: The nonsurgical management of vascular lesions. Facial Plast Surg Clin North Am; 2001 Nov;9(4):601-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hemangioma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Anticoagulants / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Facial Neoplasms / drug therapy. Glucocorticoids / administration & dosage. Hemangioendothelioma / drug therapy. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Interferons / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590946.001).
  • [ISSN] 1064-7406
  • [Journal-full-title] Facial plastic surgery clinics of North America
  • [ISO-abbreviation] Facial Plast Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Glucocorticoids; 0 / Heparin, Low-Molecular-Weight; 5J49Q6B70F / Vincristine; 9008-11-1 / Interferons
  • [Number-of-references] 60
  •  go-up   go-down






Advertisement